#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Isocyclosporin A Eye Drops for Adults with Atopic Keratoconjunctivitis

2 1 1

What is this study about?

This clinical trial is focused on studying a condition called Atopic Keratoconjunctivitis (AKC), which affects the eyes and can cause symptoms like itching, redness, and discomfort. The study will test the safety and effectiveness of a medication called Isocyclosporin A, which is administered as eye drops. The trial will compare two different doses of Isocyclosporin A to a placebo, which is a substance with no active medication, to see if the medication can improve symptoms in patients with AKC.

The purpose of the study is to determine if at least one of the doses of Isocyclosporin A is better than the placebo in reducing eye itching. Participants in the study will use the eye drops for four weeks, and their symptoms will be monitored during this time. After the treatment period, there will be a follow-up period of two weeks to continue observing the effects of the medication. The study aims to provide valuable information on how well Isocyclosporin A works for people with AKC and whether it is safe to use.

Throughout the study, participants will be asked to report any changes in their symptoms, such as itching, tearing, and discomfort, as well as any side effects they may experience. The study will also assess the overall quality of life for participants, as well as any changes in their vision. By the end of the study, researchers hope to gather enough data to understand the potential benefits and risks of using Isocyclosporin A for treating Atopic Keratoconjunctivitis.

1 joining the study

Upon joining the study, the patient will be informed about the trial procedures and will need to provide consent. This involves reading and signing a consent form to confirm understanding and agreement to participate.

2 baseline assessment

The patient will undergo a baseline assessment to evaluate their current condition. This includes measuring the ocular itching score using a visual analogue scale and assessing other symptoms such as tearing, discomfort, mucous discharge, and photophobia.

3 medication administration

The patient will be randomly assigned to receive either Isocyclosporin A eye drop solution or a vehicle (placebo).

The eye drops will be administered twice daily (BID) or four times daily (QID) depending on the assigned group.

The treatment will last for 4 weeks.

4 weekly assessments

Throughout the 4-week treatment period, the patient will have weekly assessments to monitor changes in ocular symptoms and signs.

These assessments will include measuring the ocular itching score and other symptoms using standardized scales.

5 end of treatment assessment

At the end of the 4-week treatment period, a comprehensive assessment will be conducted to evaluate the mean change from baseline in ocular symptoms and signs.

The primary focus will be on the change in the ocular itching score.

6 follow-up period

After completing the treatment, the patient will enter a 2-week follow-up period.

During this time, additional assessments will be conducted to monitor any changes in symptoms and to ensure the patient’s safety.

Who Can Join the Study?

  • Must be a male or female aged 18 years or older.
  • Must have a diagnosis of Atopic Keratoconjunctivitis (AKC) in both eyes. This includes an eye itching score of 50 or more on a visual scale and at least one of the following conditions in one eye:
    • Presence of a reaction in the inner eyelid or around the eye.
    • A combined symptom score of 4 or more, which includes symptoms like itching, tearing, eye discomfort, sensitivity to light, and mucous discharge.
    • A score of 2 or more for superficial punctate keratitis, which is a type of eye surface damage, measured by a special eye stain test.
    • A redness score of 1 or more in the white part of the eye on a scale of 0 to 3.
  • Must have a good level of vision, with a score of +1.0 logMAR or better in both eyes.
  • If female and able to have children, must have a negative pregnancy test at the start of the study.
  • Must have read, signed, and dated the informed consent form before any study procedures begin.
  • Must be able and willing to follow the study procedures.
  • If using skin treatments for allergies, they must be stable for 30 days before the study and expected to remain stable during the study. These treatments should not be used on the eye surface.
  • If using treatments for atopic dermatitis (a type of skin allergy), they must be stable for 30 days before the study and expected to remain stable during the study.
  • If using eye medications for conditions other than AKC, they can be included if the medications are not for allergies, steroids, or certain immune treatments, and have been stable for at least 3 months before the study.

Who Cannot Join the Study?

  • Patients who are not adults cannot participate. This means only individuals who are 18 years or older can join.
  • Patients who do not have Atopic Keratoconjunctivitis (AKC) cannot participate. AKC is a condition that affects the eyes, causing itching and inflammation.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups who might need special protection, like children or people with certain disabilities.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Azienda Ospedaliero Universitaria Careggi Florence Italy
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli Naples Italy

Other Sites

Site Name City Country Status
Multimedica S.p.A. Milan Italy
Universita’ Campus Bio-medico Di Roma Rome Italy
Universita’ Degli Studi Di Verona Verona Italy
Ailkfhu Uvuur Savovcqja Lwxwms Dm Bmqmvyw Bologna Italy
Ugadksinof Dmhub Sldyz Da Rkkd Ls Sadieiuv Rome Italy

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Italy Italy
Not recruiting
25.03.2024

Trial locations

Investigated drugs:

Isocyclosporin A Eye Drop Solution is being tested in this clinical trial. It is an eye drop medication designed to help reduce symptoms of atopic keratoconjunctivitis (AKC), a condition that causes inflammation and itching in the eyes. The trial aims to determine if this medication can effectively improve ocular itching in adults with AKC.

Investigated diseases:

Atopic Keratoconjunctivitis – Atopic keratoconjunctivitis (AKC) is a chronic inflammatory condition affecting the eyes, primarily seen in individuals with a history of atopic dermatitis. It involves both the cornea and the conjunctiva, leading to symptoms such as intense itching, redness, tearing, and discomfort. Over time, the condition can cause thickening of the eyelids and changes in the corneal surface, potentially affecting vision. Patients may also experience mucous discharge and sensitivity to light. The disease often progresses with periods of exacerbation and remission, influenced by environmental factors and allergens. It is considered a rare disease and requires careful management to prevent complications.

Trial ID:
2023-508907-19-00
Protocol code:
ICY0123
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study testing DFL24498 eye drop solution to improve eye itching in adults with atopic keratoconjunctivitis

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Study on Ciclosporin for Treating Atopic Keratoconjunctivitis in Adults

    Recruiting

    2 1 1
    Investigated drugs:
    Denmark